Treatment of Gastroesophageal Junction Carcinoma

Video

This video reviews first- and second-line treatment options for patients with carcinoma of the gastroesophageal junction.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      In this video, Ian Chau, MD, of Royal Marsden Hospital in London, reviews first- and second-line treatment options for patients with carcinoma of the gastroesophageal junction.

      In the first-line setting, different standards for treatment duration exist around the world, including the idea of rechallenging with the same chemotherapy if a patient achieves stable disease.

      In the second-line setting, Chau discusses the use of chemotherapy and ramucirumab.

      Recent Videos
      Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
      Genetic Data May Inform Personalized Radiotherapy Strategies for Cancer Care
      Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
      Molecular Diagnostics, PIPAC Appear "Exciting" in GI Cancer Surgical Care
      Future work may focus on optimizing symptom management associated with percutaneous transesophageal gastrostomy placement in malignant bowel obstructions.
      Prospective Study May Clarify PTEG Benefits in Malignant Bowel Obstruction
      Post-operative length of stay ranged from 4 to 9 days for patients who underwent percutaneous transesophageal gastrostomy for malignant bowel obstructions.
      PTEG Elicits Encouraging Technical Outcomes in Malignant Bowel Obstruction
      Data Show Underutilization of Appendectomy in Appendix Cancer Population
      Data Show Underutilization of Appendectomy in Appendix Cancer Population
      Treatment with KRAS inhibitors may help mitigate a common driver of genetic alteration across a majority of pancreatic cancers.
      Novel Treatments May Have the Potential to Impact GI Cancer Care
      Various methods of communication ensure that members from radiation oncology, pathology, and other departments are on the same page regarding treatment.
      Making a ‘World of Difference’ Via Multidisciplinary Care in GI, GU Cancers
      Staged Colectomy May Be Preferable to Upfront Colectomy in Appendix Cancer
      Staged Colectomy May Be Preferable to Upfront Colectomy in Appendix Cancer
      Updated results from the BREAKWATER study seemed to be most impactful to the CRC space, according to Michael J. Pishvaian, MD, PhD.
      CRC Yields Most Prevalent Data at Recent GI Meeting
      No Subgroups Benefit From HIPEC/CRS in Colorectal Peritoneal Metastasis
      No Subgroups Benefit From HIPEC/CRS in Colorectal Peritoneal Metastasis
      Related Content
      Antitumor activity was observed in patients with gastroesophageal adenocarcinoma treated with the combination regardless of chemotherapy type.

      Zanidatamab Displays Safety, Efficacy in HER2-Expressing Gastric Cancer

      Roman Fabbricatore
      May 19th 2025
      Article

      Antitumor activity was observed in patients with gastroesophageal adenocarcinoma treated with the combination regardless of chemotherapy type.

      The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

      Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

      Marwan G. Fakih, MD
      February 24th 2025
      Podcast

      The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

      The trial initiation is based on phase 1/2 IDeate-PanTumor01 trial results presented at the 2022 and 2023 European Society for Medical Oncology Congress.

      Phase 3 IDeate-Esophageal01 Trial Initiated for Unresectable ESCC

      Roman Fabbricatore
      May 19th 2025
      Article

      The trial initiation is based on phase 1/2 IDeate-PanTumor01 trial results presented at the 2022 and 2023 European Society for Medical Oncology Congress.

      Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

      Educating Patients and Clinicians on End-of-Life Care and Discussions

      Kelley A. Rone, DNP, RN, AGNP-c
      November 11th 2024
      Podcast

      Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

      The safety profile of TFOX was consistent with data reported in previous studies, and no new safety signals were identified.

      TFOX Regimen Enhances Efficacy vs FOLFOX in HER2-Negative Gastric Cancer

      Roman Fabbricatore
      May 11th 2025
      Article

      The safety profile of TFOX was consistent with data reported in previous studies, and no new safety signals were identified.

      "Our preliminary results showed that the efficacy of fruquintinib combined with capecitabine is promising with well tolerance as maintenance therapy in RAS/BRAF wild-type mCRC,” according to lead study author, Kai Ou.

      Fruquintinib Combo Shows Early Activity in RAS/BRAF+ Metastatic CRC

      Courtney Flaherty
      May 9th 2025
      Article

      At the time of analysis, the median progression-free survival was not reached with fruquintinib plus capecitabine in a phase 1/2 trial.